Explore

Rapid Read Rapid Read
FDA Removes Black Box Warnings from Menopause HRT Products, Impacting Women's Health Choices

FDA Removes Black Box Warnings from Menopause HRT Products, Impacting Women's Health Choices

The FDA has recently removed the broad 'black box' warnings from most menopause hormone replacement therapy (HRT) products, which previously highlighted risks such as cardiovascular disease, breast cancer, and dementia. This change is part of a broader shift in the medical community towards a more nuanced understanding of HRT's risks and benefits. The removal of these warnings reflects updated research and a growing recognition of the individualized nature of menopause treatment. Women experiencing menopause symptoms are encouraged to seek personalized medical advice, as the decision to use HRT should consider factors like symptom severity, other health conditions, and personal health risks. The change comes after years of hesitation in the medical community following the misinterpretation of the Women’s Health Initiative study, which had previously led to a decline in HRT use.
Trendline Trendline
FDA Raises Concerns Over Amgen's Tavneos, Approves Regeneron's Gene Therapy

FDA Raises Concerns Over Amgen's Tavneos, Approves Regeneron's Gene Therapy

FDA Raises Concerns Over Amgen's Tavneos, Approves Regeneron's Gene Therapy
Trendline Trendline
FDA Advisory Committee Rejects AstraZeneca's Breast Cancer Drug Due to Trial Design Concerns

FDA Advisory Committee Rejects AstraZeneca's Breast Cancer Drug Due to Trial Design Concerns

FDA Advisory Committee Rejects AstraZeneca's Breast Cancer Drug Due to Trial Design Concerns
Trendline Trendline
Eli Lilly's Weight Loss Pill Foundayo Gains Traction Among New Patients Without Full Marketing Push

Eli Lilly's Weight Loss Pill Foundayo Gains Traction Among New Patients Without Full Marketing Push

Eli Lilly's Weight Loss Pill Foundayo Gains Traction Among New Patients Without Full Marketing Push
Rapid Read Rapid Read
FDA Halts Newron's Schizophrenia Study After Patient Death

FDA Halts Newron's Schizophrenia Study After Patient Death

The FDA has paused patient enrollment in Newron Pharmaceuticals' Phase 3 ENIGMA-TRS 2 trial for its schizophrenia drug, evenamide, following a patient death. The death occurred outside the U.S. and was deemed unrelated to the drug. The trial, which is testing evenamide for treatment-resistant schizophrenia, continues in other countries, including India and Argentina. Evenamide is an antipsychotic agent that works by blocking voltage-gated sodium channels to restore glutamate balance. Phase 2 data showed that evenamide reduced disease severity and psychosis symptoms, with benefits maintained over a year. Newron is also conducting another study, ENIGMA-TRS 1, across multiple regions.
Trendline Trendline
Experts Express Concerns Over GLP-1 Weight Loss Pills Amid Cultural Shift

Experts Express Concerns Over GLP-1 Weight Loss Pills Amid Cultural Shift

Experts Express Concerns Over GLP-1 Weight Loss Pills Amid Cultural Shift
Trendline Trendline
FDA Panel Delivers Mixed Verdict on AstraZeneca's Cancer Drugs

FDA Panel Delivers Mixed Verdict on AstraZeneca's Cancer Drugs

FDA Panel Delivers Mixed Verdict on AstraZeneca's Cancer Drugs
Rapid Read Rapid Read
FDA Advisory Committee to Review AstraZeneca's Cancer Drug Applications Amid Concerns

FDA Advisory Committee to Review AstraZeneca's Cancer Drug Applications Amid Concerns

The FDA is set to hold its first drug-related advisory committee meeting in nine months to evaluate AstraZeneca's applications for two cancer drugs. The meeting will focus on the oral SERD drug camizestrant for HR-positive, HER2-negative breast cancer and the AKT inhibitor Truqap for metastatic hormone-sensitive prostate cancer. The FDA has raised questions about the clinical benefits and trial designs of these drugs, particularly regarding the validity of results and the timing of treatment interventions. The advisory panel will assess whether AstraZeneca has provided sufficient evidence to support the clinical benefits of these drugs.
Trendline Trendline
FDA Halts Newron's Schizophrenia Study After Patient Death, Safety Review Underway

FDA Halts Newron's Schizophrenia Study After Patient Death, Safety Review Underway

FDA Halts Newron's Schizophrenia Study After Patient Death, Safety Review Underway
Rapid Read Rapid Read
FDA Advisory Committee Recommends TRUQAP for PTEN-Deficient Prostate Cancer

FDA Advisory Committee Recommends TRUQAP for PTEN-Deficient Prostate Cancer

The FDA's Oncologic Drugs Advisory Committee has recommended AstraZeneca's TRUQAP (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) for treating PTEN-deficient metastatic hormone-sensitive prostate cancer. The recommendation is based on the CAPItello-281 Phase III trial, which demonstrated a favorable benefit-risk profile for the drug combination. The trial showed a significant reduction in the risk of disease progression and improved survival outcomes for patients. This marks the first targeted treatment combination to show benefits in this specific subtype of prostate cancer, addressing a significant unmet need for patients with limited treatment options.
Rapid Read Rapid Read
FDA Halts Newron's U.S. Enrollment in Schizophrenia Study After Patient Death

FDA Halts Newron's U.S. Enrollment in Schizophrenia Study After Patient Death

The FDA has temporarily paused Newron Pharmaceuticals' enrollment of new patients in the U.S. for its Phase 3 ENIGMA-TRS 2 trial, following a patient death. The trial is testing evenamide, an antipsychotic agent for treatment-resistant schizophrenia. The death occurred outside the U.S. and was deemed unrelated to the drug. Despite the pause in the U.S., the trial continues in other countries, including India and Argentina. Evenamide works by modulating glutamate levels in the brain, and previous studies have shown it reduces schizophrenia symptoms. Newron is also conducting another trial, ENIGMA-TRS 1, across multiple regions.
Trendline Trendline
Sprout Pharmaceuticals Recognized by TIME for Influential Role in Health and Life Sciences

Sprout Pharmaceuticals Recognized by TIME for Influential Role in Health and Life Sciences

Sprout Pharmaceuticals Recognized by TIME for Influential Role in Health and Life Sciences